ThermoGenesis reveals intellectual property acquisition by ImmuneCyte

By Akshay Kedari  Date: 2020-04-14

ThermoGenesis reveals intellectual property acquisition by ImmuneCyte

ThermoGenesis Holdings, Inc. has recently announced the acquisition of intellectual property by ImmuneCyte Life Sciences, its joint venture. The acquisition has been made by ThermoGenesis, a market leader and pioneer in the development & commercialization of automated cell processing technologies, to develop full human antibody therapeutics for COVID-19 disease.

The intellectual property that has been procured includes 4 monoclonal antibody drug candidates with high affinity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as tools for quantifying and screening efficacy of the neutralizing antibodies. These high-affinity antibodies have been obtained by screening the enriched libraries of B cell from people who have recovered from the COVID-19 disease recently. These technologies were developed by a team of researchers who work under East China Normal University, which is a prestigious university in China. The deal also includes an upfront cash payment for an undisclosed sum as well as low double-digit revenue sharing for the drug candidates.

The recent acquisition is another step towards the development of drug candidates or vaccine for emergency treatment of the patients infected by coronavirus. The convalescent plasma therapy has been applied for this treatment by giving current patients an infusion of plasma from individuals recovered from the disease. ThermoGenesis is developing this therapy by using its IgG/IgM Antibody Fast Detection Kit for SARS-CoV-2. Through the combination of this detection kit with the newly acquired technology by ImmuneCyte, the company will detect individuals who have acquired protective immunity against the coronavirus. Its proprietary cell processing platform will then allow the simultaneous isolation of immune cells and convalescent plasma for the effective development of potential anti-COVID-19 antibody.

The entrance of coronavirus into the cells can be blocked effectively by neutralizing antibodies, which are key effectors in the convalescent plasma, thus achieving anti-viral effects. The recent acquisition can lead to the further development of purified anti-COVID-19 monoclonal and polyclonal neutralizing antibodies as these can be more potent and safer with higher efficacy as compared to convalescent plasma.

Source credit:

https://thermogenesis.com/thermogenesis-announces-its-immunecyte-joint-venture-acquires-key-technologies-to-develop-fully-human-polyclonal-and-monoclonal-antibody-therapeutics-for-covid-19/

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Mark Zuckerberg planning to rebrand Facebook to reflect metaverse focus

Mark Zuckerberg planning to rebrand Facebook to reflect metaverse focus

By Akshay Kedari

There have been many businesses that have rebranded themselves to alter their identity with time. Following the league, social networking giant Facebook is also reportedly planning to rebrand the firm with a new name. On October 28, Chief Executive ...

Formula One teams to test second-generation biofuel during 2022 season

Formula One teams to test second-generation biofuel during 2022 season

By Akshay Kedari

The leading motorsport intends to achieve net-zero carbon status by the end of this decade. F1 has ruled out switching to an all-electric powertrain such as in Formula E. With increasing significance towards green mobility, Formula One teams are...

Apple’s iPhone 13 production may take a hit due to global chip shortage

Apple’s iPhone 13 production may take a hit due to global chip shortage

By Akshay Kedari

Apple Inc. is likely to cut down production of its iPhone 13 model by approximately 10 million units on account of the global chip shortage. The American multinational technology company was previously expected to manufacture 90 million units of the ...

Israel's GoTo Global acquires German e-moped sharing platform emmy

Israel's GoTo Global acquires German e-moped sharing platform emmy

By Akshay Kedari

Israel-based multimodal vehicle sharing services provider GoTo Global Mobility Ltd. has reportedly acquired Germany’s shared e-scooter company emmy. The acquisition will allow GoTo Global to enter the German market as well as accelerate its Eur...

German airline Lufthansa adds four new planes to its A350 fleet

German airline Lufthansa adds four new planes to its A350 fleet

By Akshay Kedari

Deutsche Lufthansa AG recently revealed that it has agreed to take four new Airbus A350-900 long-haul passenger aircraft on lease, utilizing newer planes that are left grounded as airlines reorganize their balance sheets in the wake of the ...